Patients with BRCA-mutant ovarian cancer saw an improved progression-free survival with Lynparza, according to a recent study. There was a 70 percent reduction in the risk of progression or death with ...

The benefit of PARP inhibitors varied significantly based on the tumor's molecular profile, particularly its homologous recombination repair capability. While patients with deficiencies in this ...

NEW YORK — Scientists have identified a potentially game-changing treatment approach for ovarian cancer, one of the deadliest forms of the disease that kills roughly 12,740 American women each year.

Hua-Ying Fan, PhD, hopes that her team's latest discovery could help the almost 21,000 people who are expected to receive an ovarian cancer diagnosis this year. Fan's team at The University of New ...

Researchers at the University of Colorado Cancer Center have discovered a novel therapy combination that could offer new hope to ovarian cancer patients who do not respond to existing treatments.

Ovarian cancer treatment faces challenges with high relapse and drug resistance rates, despite initial chemotherapy effectiveness. Cytokines like IL-6 and IL-11 are associated with complex tumor ...

KEYNOTE-B96 is the first trial of an immune checkpoint inhibitor-based treatment regimen in platinum-resistant recurrent ovarian cancer to show a statistically significant improvement in OS versus ...

Hua-Ying Fan, PhD, hopes that her team's latest discovery could help the almost 21,000 people who are expected to receive an ovarian cancer diagnosis this year. Subscribe to our newsletter for the ...